Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871759 | 0.73 | — | — | |
| SCHEMBL9440546 | 0.73 | NOTUM (0.45) | BRS3 | |
| Hydrochloric Acid SCHEMBL4739527 | 0.71 | NOTUM (0.44) | BRS3 | |
| SCHEMBL8029514 | 0.70 | ALDH1A1 (0.39) | — | |
| SCHEMBL14895448 | 0.67 | ALDH1A1 (0.40) | BRS3CYP19A1 | |
| SCHEMBL17673656 | 0.64 | P2RX7 (0.34) | — | |
| SCHEMBL1428276 | 0.64 | KDM4E (0.67) | — | |
| SCHEMBL246008 | 0.64 | CYP1A2 (0.46) | — | |
| SCHEMBL9024253 | 0.63 | POLB (0.31) | — | |
| SCHEMBL7402637 | 0.63 | ADH5 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133157-B2 | HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-09-15 | — | — | US | claimed |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-10-09 | — | — | US | claimed |
| EP-2771332-A1 | HIV PROTEASE INHIBITORS | Merck Canada Inc. (CA) | 2014-09-03 | — | — | EP | claimed |
| EP-1911754-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2013-10-09 | — | — | EP | claimed |
| WO-2013059928-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2013-05-02 | — | — | WO | claimed |
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | claimed |
| US-7825242-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-11-02 | — | — | US | claimed |
| US-7790734-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | claimed |
| US-7723344-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-05-25 | — | — | US | claimed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | claimed |
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | claimed |
| US-20050065145-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | claimed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | claimed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | claimed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | claimed |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | claimed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| US-5948696-A | LIBRARY OF COMPOUNDS LINKED TO SOLID SUPPORT; SUPPORT ALSO HAS IDENTIFIER MOLECULE (TAG); FOR USE IN SCREENING BIOLOGICALLY ACTIVE MOLECULES SUCH AS ENZYME INHIBITORS | PHARMACOPEIA, INC. (US) | 1999-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | BRS3 223/4885CYP19A1 2190/4885 |
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | BRS3 565/4885CYP19A1 2037/4885 |
| US-20050065145-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | BRS3 669/4885CYP19A1 1907/4885 |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP3, DPP4 | BRS3 466/4885CYP19A1 2330/4885 |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, PRSS3 | BRS3 2404/4885CYP19A1 479/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | BRS3 356/4885CYP19A1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.